Immunocore

company

About

Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$140M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
nasdaq:IMCR
Legal Name
Immunocore Limited

Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.


Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
8
$1.06B £2.40M
Immunocore has raised a total of $1.06B £2.40M in funding over 2 rounds. Their latest funding was raised on Jul 18, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 18, 2022 Post-IPO Equity $140M 3 Detail
Feb 4, 2021 IPO $258.31M Detail
Jan 11, 2021 Series C $75M 1 BlackRock Detail
Jan 11, 2021 Debt Financing $100M 1 Oxford Finance LLC Detail
Mar 2, 2020 Series B $130M 9 General Atlantic Detail

Employee Profiles

Number of Employee Profiles
5
Immunocore has 5 current employee profiles, including Employee Ian Laing
Employee
Executive
Board member
Employee
Executive